JP5758900B2 - グルコピラノシル置換ベンジルベンゼン誘導体の調製方法 - Google Patents
グルコピラノシル置換ベンジルベンゼン誘導体の調製方法 Download PDFInfo
- Publication number
- JP5758900B2 JP5758900B2 JP2012531333A JP2012531333A JP5758900B2 JP 5758900 B2 JP5758900 B2 JP 5758900B2 JP 2012531333 A JP2012531333 A JP 2012531333A JP 2012531333 A JP2012531333 A JP 2012531333A JP 5758900 B2 JP5758900 B2 JP 5758900B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- mixture
- reaction
- range
- organic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *OCC([C@@](C([C@]1O*)O*)O*)OC1(c(cc1Cc(cc2)ccc2O*)ccc1Cl)O* Chemical compound *OCC([C@@](C([C@]1O*)O*)O*)OC1(c(cc1Cc(cc2)ccc2O*)ccc1Cl)O* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Packaging Of Annular Or Rod-Shaped Articles, Wearing Apparel, Cassettes, Or The Like (AREA)
- Wrapping Of Specific Fragile Articles (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24714409P | 2009-09-30 | 2009-09-30 | |
US61/247,144 | 2009-09-30 | ||
PCT/EP2010/064120 WO2011039108A2 (en) | 2009-09-30 | 2010-09-24 | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013505975A JP2013505975A (ja) | 2013-02-21 |
JP5758900B2 true JP5758900B2 (ja) | 2015-08-05 |
Family
ID=43736212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012531333A Active JP5758900B2 (ja) | 2009-09-30 | 2010-09-24 | グルコピラノシル置換ベンジルベンゼン誘導体の調製方法 |
Country Status (25)
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2295422A3 (de) * | 2004-03-16 | 2012-01-04 | Boehringer Ingelheim International GmbH | Glucopyranosylsubstituierte Benzolderivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
UA91546C2 (uk) * | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
ATE491700T1 (de) * | 2005-09-08 | 2011-01-15 | Boehringer Ingelheim Int | KRISTALLINE FORMEN VON 1-CHLORO-4-(ß-D- |
PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
WO2008049923A1 (en) * | 2006-10-27 | 2008-05-02 | Boehringer Ingelheim International Gmbh | CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS |
CL2008002427A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
CA2706018C (en) | 2007-11-30 | 2015-11-24 | Boehringer Ingelheim International Gmbh | 1, 5-dihydro-pyrazolo [3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators for the treatment of cns disorders |
UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
CA2736304A1 (en) | 2008-09-08 | 2010-03-11 | Boehringer Ingelheim International Gmbh | Pyrazolopyrimidines and their use for the treatment of cns disorders |
CN104906582A (zh) | 2009-02-13 | 2015-09-16 | 勃林格殷格翰国际有限公司 | 包含sglt2抑制剂、dpp-iv抑制剂和任选的另一种抗糖尿病药的药物组合物及其用途 |
SI2414363T1 (sl) | 2009-03-31 | 2014-04-30 | Boehringer Ingelheim Gmbh | Derivati 1-heterociklil-1,5-dihidro-pirazolo/3,4-d/pirimidin-4-ona in njihova uporaba kot modulatorji za PDE9A |
PL2483286T3 (pl) | 2009-09-30 | 2017-04-28 | Boehringer Ingelheim International Gmbh | Sposób wytwarzania postaci krystalicznej 1-chloro-4-(β-D-glukopiranoz-1-ylo)-2-[4-((S)-tetrahydrofuran-3-yloksy)-benzylo]-benzenu |
CN102574829B (zh) | 2009-09-30 | 2015-07-01 | 贝林格尔.英格海姆国际有限公司 | 吡喃葡萄糖基取代的苄基-苯衍生物的制备方法 |
UY32919A (es) | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos |
KR101918909B1 (ko) | 2010-08-12 | 2018-11-15 | 베링거 인겔하임 인터내셔날 게엠베하 | 6사이클로알킬1,5디하이드로피라졸로[3,4d]피리미딘4온 유도체 및 이의 pde9a 억제제로서의 용도 |
US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
JP5835598B2 (ja) | 2011-06-03 | 2015-12-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 神経弛緩剤で治療されている患者において代謝性障害を治療するためのsglt−2阻害剤 |
US20130035298A1 (en) | 2011-07-08 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US9193751B2 (en) | 2012-04-10 | 2015-11-24 | Theracos, Inc. | Process for the preparation of benzylbenzene SGLT2 inhibitors |
WO2013152476A1 (en) * | 2012-04-10 | 2013-10-17 | Theracos, Inc. | Process for the preparation of benzylbenzene sglt2 inhibitors |
FI2981269T3 (fi) | 2013-04-04 | 2023-09-27 | Boehringer Ingelheim Vetmedica Gmbh | Aineenvaihduntahäiriöiden hoito hevoseläimillä |
PT2981271T (pt) | 2013-04-05 | 2019-02-19 | Boehringer Ingelheim Int | Utilizações terapêuticas de empagliflozina |
US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
MX2021004308A (es) | 2013-04-18 | 2022-10-26 | Boehringer Ingelheim Int | Empagliflozina para usarse en el tratamiento de micro y macroalbuminuria. |
CA2889699C (en) | 2013-09-27 | 2017-06-06 | Sunshine Lake Pharma Co., Ltd. | Glucopyranosyl derivatives and their uses in medicine |
EP4285995A3 (en) | 2013-12-17 | 2024-02-28 | Boehringer Ingelheim Vetmedica GmbH | An sglt-2 inhibitor for use in the treatment of a metabolic disorder in feline animals |
US9902751B2 (en) | 2013-12-30 | 2018-02-27 | Mylan Laboratories Limited | Process for the preparation of empagliflozin |
SI3485890T1 (sl) | 2014-01-23 | 2023-09-29 | Boehringer Ingelheim Vetmedica Gmbh | Inhibitorji SGLT2 za zdravljenje presnovnih motenj pri pasjih živalih |
DK3721882T3 (da) | 2014-04-01 | 2024-10-21 | Boehringer Ingelheim Vetmedica Gmbh | Behandling af hypofyse pars intermedia-dysfunktion hos hestedyr |
MX388192B (es) | 2014-09-25 | 2025-03-19 | Boehringer Ingelheim Vetmedica Gmbh | Tratamiento de combinación y/o prevención de trastornos metabólicos en animales equinos. |
US10294325B2 (en) | 2016-01-04 | 2019-05-21 | National Technology & Engineering Solutions Of Sandia, Llc | Halo-containing anion exchange membranes and methods thereof |
US10053535B2 (en) | 2016-01-04 | 2018-08-21 | National Technology & Engineering Solutions Of Sandia, Llc | Poly(phenylene)-based anion exchange polymers and methods thereof |
JP2019500477A (ja) | 2016-01-04 | 2019-01-10 | ナショナル テクノロジー アンド エンジニアリング ソリューションズ オブ サンディア, エルエルシー | ディールスアルダーポリフェニレンポリマーの官能化 |
EP3526229B1 (en) | 2016-10-13 | 2021-04-28 | Boehringer Ingelheim International GmbH | Process for preparing glucopyranosyl-substituted benzyl-benzene derivatives |
JP2019531320A (ja) | 2016-10-19 | 2019-10-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ssao/vap−1阻害剤とsglt2阻害剤とを含む組合せ、その使用 |
KR20190084096A (ko) | 2016-11-10 | 2019-07-15 | 베링거 인겔하임 인터내셔날 게엠베하 | 약제학적 조성물, 치료 방법 및 이의 용도 |
CN108794548B (zh) * | 2017-04-28 | 2023-06-16 | 正大天晴药业集团股份有限公司 | 制备恩格列净及其中间体的方法 |
US11046676B2 (en) | 2017-06-05 | 2021-06-29 | Laurus Labs Limited | Process for preparation of empagliflozin or its co-crystals, solvates and their polymorphs thereof |
CN107163033A (zh) * | 2017-06-15 | 2017-09-15 | 扬子江药业集团北京海燕药业有限公司 | 一种高纯度依帕列净的制备方法 |
CN109988161A (zh) * | 2017-12-29 | 2019-07-09 | 徐州万邦金桥制药有限公司 | 一种适合工业化生产恩格列净的制备方法 |
CN108178751A (zh) * | 2018-01-30 | 2018-06-19 | 扬州工业职业技术学院 | 一种恩格列净中间体的合成方法 |
US10479866B1 (en) | 2018-02-28 | 2019-11-19 | National Technology & Engineering Solutions Of Sandia, Llc | Block copolymers including poly(phenylene) and methods thereof |
JP2021520394A (ja) | 2018-04-17 | 2021-08-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物、処置方法及びその使用 |
US20210275558A1 (en) | 2018-07-25 | 2021-09-09 | Boehringer Ingelheim International Gmbh | Methods for treating, pharmaceutical compositions and uses thereof |
WO2020039394A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | New drug combinations |
CN109456314A (zh) * | 2018-10-19 | 2019-03-12 | 威海迪素制药有限公司 | 一种恩格列净的制备方法 |
PT3873600T (pt) | 2018-10-29 | 2023-12-15 | Boehringer Ingelheim Int | Derivados de piridinil sulfonamida, composições farmacêuticas e suas utilizações |
EP3873599B1 (en) | 2018-10-29 | 2023-09-27 | Boehringer Ingelheim International GmbH | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof |
CN111233915B (zh) * | 2018-11-28 | 2023-09-22 | 上海科胜药物研发有限公司 | 一种2,3,4,6-四-o-三甲基硅基-d-葡萄糖酸内酯的制备方法 |
CN110655511B (zh) * | 2019-05-31 | 2020-10-16 | 北京莱瑞森医药科技有限公司 | 一种高纯度恩格列净的制备和精制方法 |
CN112812107B (zh) * | 2019-11-18 | 2024-03-15 | 上海启讯医药科技有限公司 | 一种sglt-2抑制剂及中间体的制备方法 |
CN114727624A (zh) | 2019-11-28 | 2022-07-08 | 勃林格殷格翰动物保健有限公司 | Sglt-2抑制剂在非人哺乳动物的停奶中的用途 |
CN110759941B (zh) * | 2019-11-29 | 2022-08-30 | 上海网义化工有限公司 | 一种D-葡萄糖酸-γ-内酯及其中间体的制备方法 |
CN110872216A (zh) * | 2019-12-06 | 2020-03-10 | 南京恒道医药科技有限公司 | 一种反应分离耦合生产(2-氯-5-碘苯基)-4-氟苯甲基酮的方法及装置 |
CN110903315A (zh) * | 2019-12-16 | 2020-03-24 | 上海网义化工有限公司 | 一种D-葡萄糖酸-γ-内酯中间体的制备方法 |
CN118615450A (zh) | 2020-02-17 | 2024-09-10 | 勃林格殷格翰动物保健有限公司 | Sglt-2抑制剂用于预防和/或治疗猫科动物的心脏疾病的用途 |
JP2023520899A (ja) | 2020-04-07 | 2023-05-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 頭痛障害の処置のための方法 |
CN111410639B (zh) * | 2020-04-14 | 2021-02-26 | 天津法莫西医药科技有限公司 | 一种恩格列净中间体杂质的制备方法 |
CN112194655B (zh) * | 2020-10-15 | 2022-08-09 | 通化东宝药业股份有限公司 | 一种恩格列净的制备方法 |
KR20220068805A (ko) | 2020-11-19 | 2022-05-26 | 한미약품 주식회사 | 신규한 글루코스 유도체 |
CN113480497B (zh) * | 2021-07-27 | 2023-02-28 | 山东铂源药业股份有限公司 | 一种恩格列净关键中间体的合成方法 |
WO2023006718A1 (en) | 2021-07-28 | 2023-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines |
KR20240040106A (ko) | 2021-07-28 | 2024-03-27 | 베링거잉겔하임베트메디카게엠베하 | 비-사람 포유류에서 신장 질환의 예방 및/또는 치료를 위한 sglt-2 억제제의 용도 |
US20240269105A1 (en) | 2021-07-28 | 2024-08-15 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals |
CN114716425B (zh) * | 2022-04-11 | 2023-09-01 | 沧州那瑞化学科技有限公司 | 芳香杂环取代亚甲基的化合物的合成方法 |
JP2025516857A (ja) | 2022-05-25 | 2025-05-30 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | Sglt-2阻害薬を含む水性医薬組成物 |
CN115231992B (zh) * | 2022-06-30 | 2024-08-27 | 济南鼎皓医药科技有限公司 | 一种(2-氯-5-碘苯基)(4-氟苯基)甲酮的制备方法 |
CN115232179A (zh) * | 2022-08-15 | 2022-10-25 | 江西天戌药业有限公司 | 一种恩格列净中间体杂质的制备方法 |
AU2024233233A1 (en) | 2023-03-06 | 2025-09-11 | Boehringer Ingelheim Vetmedica Gmbh | Systems for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s) |
WO2024240633A1 (en) | 2023-05-24 | 2024-11-28 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan |
TW202508593A (zh) | 2023-05-24 | 2025-03-01 | 德商百靈佳殷格翰維美迪加股份有限公司 | 包含一或多種sglt-2抑制劑及匹莫苯坦(pimobendan)及/或替米沙坦(telmisartan)之非人類哺乳動物心臟病之組合治療及/或預防 |
CN116715569A (zh) * | 2023-05-26 | 2023-09-08 | 雅邦绿色过程与新材料研究院南京有限公司 | 一种4,4’-二氟二苯甲酮的制备方法 |
Family Cites Families (154)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
NL167151C (nl) * | 1971-04-09 | 1981-11-16 | Acf Chemiefarma Nv | Werkwijze ter bereiding van geneesmiddelen met anti-parasitaire werking op basis van halogeen bevatten- de 2,2'-methyleendifenolderivaten, alsmede werkwijze ter bereiding van deze geneeskrachtige verbindingen. |
NO154918C (no) * | 1977-08-27 | 1987-01-14 | Bayer Ag | Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin. |
DE2758025A1 (de) | 1977-12-24 | 1979-07-12 | Bayer Ag | Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung |
DE2951135A1 (de) | 1979-12-19 | 1981-06-25 | Hoechst Ag, 6230 Frankfurt | Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
JPS5639056A (en) | 1980-07-16 | 1981-04-14 | Kanebo Ltd | Preparation of n,n,n',n'-tetraacylated nucleus halogenated aromatic diamine |
JPS58164502A (ja) | 1982-03-26 | 1983-09-29 | Chugai Pharmaceut Co Ltd | 除草用組成物 |
US4786755A (en) * | 1985-06-03 | 1988-11-22 | Warner-Lambert Company | Diphenic acid monoamides |
US4602023A (en) * | 1985-06-03 | 1986-07-22 | Warner-Lambert Company | Diphenic acid monoamides |
US4786023A (en) * | 1987-08-19 | 1988-11-22 | Harris Leverett D | Drafting implement holder |
US6297273B1 (en) | 1996-04-02 | 2001-10-02 | Mars, Inc. | Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions |
JPH1085502A (ja) * | 1996-09-19 | 1998-04-07 | Konica Corp | 晶析方法 |
AU6024998A (en) | 1997-01-15 | 1998-08-07 | Glycomed Incorporated | Aryl c-glycoside compounds and sulfated esters thereof |
JPH11124392A (ja) | 1997-10-21 | 1999-05-11 | Sankyo Co Ltd | C−グリコシル化されたアリールスズ化合物 |
DE19846314A1 (de) | 1998-10-08 | 2000-04-13 | Basf Ag | Polyolefinnanocomposite |
US6613806B1 (en) * | 1999-01-29 | 2003-09-02 | Basf Corporation | Enhancement of the efficacy of benzoylbenzenes |
CZ303372B6 (cs) * | 1999-08-31 | 2012-08-22 | Kissei Pharmaceutical Co., Ltd. | Glukopyranosyloxypyrazolový derivát a farmaceutická kompozice s jeho obsahem a benzylpyrazolový meziprodukt |
US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
US6498193B2 (en) | 1999-12-22 | 2002-12-24 | Trustees Of Dartmouth College | Treatment for complications of type 2 diabetes |
US6627611B2 (en) * | 2000-02-02 | 2003-09-30 | Kotobuki Pharmaceutical Co Ltd | C-glycosides and preparation of thereof as antidiabetic agents |
JP4456768B2 (ja) | 2000-02-02 | 2010-04-28 | 壽製薬株式会社 | C−配糖体を含有する薬剤 |
CZ20023023A3 (cs) | 2000-03-17 | 2003-04-16 | Kissei Pharmaceutical Co., Ltd. | Glukopyranosyloxybenzylbenzenové deriváty, léčivé směsi obsahující tyto látky a meziprodukty pro přípravu derivátů |
US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
EP1329456B1 (en) * | 2000-09-29 | 2006-08-09 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same |
US7053060B2 (en) | 2000-11-30 | 2006-05-30 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof |
TWI255817B (en) * | 2001-02-14 | 2006-06-01 | Kissei Pharmaceutical | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof |
BR0207285A (pt) | 2001-02-15 | 2004-02-10 | Pfizer Producs Inc | Agonistas de ppar |
US6936590B2 (en) * | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
JP3698067B2 (ja) * | 2001-03-30 | 2005-09-21 | Jsr株式会社 | 電子吸引性基および電子供与性基を有するモノマー、それを用いた共重合体、ならびにプロトン伝導膜 |
JP2004536047A (ja) * | 2001-04-11 | 2004-12-02 | ブリストル−マイヤーズ スクイブ カンパニー | 糖尿病処置用c−アリールグルコシドのアミノ酸複合体および方法 |
DE10139416A1 (de) | 2001-08-17 | 2003-03-06 | Aventis Pharma Gmbh | Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2003020737A1 (en) | 2001-09-05 | 2003-03-13 | Bristol-Myers Squibb Company | O-pyrazole glucoside sglt2 inhibitors and method of use |
WO2003031458A1 (en) | 2001-10-12 | 2003-04-17 | Dana-Farber Cancer Institute | Methods for synthesis of diarylmethanes |
ATE372335T1 (de) | 2002-02-01 | 2007-09-15 | Novo Nordisk As | Amide von aminoalkylsubstituierten azetidinen, pyrrolidinen, piperidinen und azepanen |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
DE10231370B4 (de) | 2002-07-11 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
TWI254635B (en) | 2002-08-05 | 2006-05-11 | Yamanouchi Pharma Co Ltd | Azulene derivative and salt thereof |
MXPA05001549A (es) * | 2002-08-08 | 2005-05-05 | Kissei Pharmaceutical | Derivado de pirazol, composicion medicinal que lo contiene, su uso medicinal, e intermediario para su produccion. |
BR122012026540B8 (pt) | 2002-08-21 | 2021-05-25 | Boehringer Ingelheim Pharma | 8-[3-amino-piperidin-1-il]-xantinas, seus sais farmacêuticamente aceitáveis, seu uso e seu processo de preparação, bem como medicamento e seu processo de preparação |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
JP3567162B1 (ja) | 2002-11-20 | 2004-09-22 | 日本たばこ産業株式会社 | 4−オキソキノリン化合物及びそのhivインテグラーゼ阻害剤としての利用 |
EP2272516A3 (en) | 2002-11-20 | 2011-03-16 | Japan Tobacco, Inc. | 4-Oxoquinoline compound and use thereof as HIV integrase inhibitor |
JP4651934B2 (ja) | 2002-12-04 | 2011-03-16 | キッセイ薬品工業株式会社 | ベンジルフェノール誘導体、それを含有する医薬組成物およびその医薬用途 |
DE10258007B4 (de) | 2002-12-12 | 2006-02-09 | Sanofi-Aventis Deutschland Gmbh | Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
DE10258008B4 (de) | 2002-12-12 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
EP1581543A4 (en) | 2003-01-03 | 2008-03-19 | Bristol Myers Squibb Co | METHODS FOR PRODUCING SGLT2 GLYCOSIS C-ARYL INHIBITORS |
US7164015B2 (en) | 2003-02-27 | 2007-01-16 | Bristol-Myers Squibb Company | Non-cryogenic process for forming glycosides |
AU2004220222B2 (en) * | 2003-03-14 | 2009-10-01 | Astellas Pharma Inc. | C-glycoside derivatives and salts thereof |
US7674486B2 (en) | 2003-05-14 | 2010-03-09 | Indus Biotech Pvt. Ltd. | Synergistic composition for the treatment of diabetes mellitus |
CA2528152A1 (en) * | 2003-06-03 | 2005-01-06 | The Regents Of The University Of California | Compositions and methods for treatment of disease with acetylated disaccharides |
JP2004359630A (ja) | 2003-06-06 | 2004-12-24 | Yamanouchi Pharmaceut Co Ltd | ジフルオロジフェニルメタン誘導体及びその塩 |
PL1651658T5 (pl) | 2003-08-01 | 2020-11-30 | Mitsubishi Tanabe Pharma Corporation | Nowe związki o działaniu inhibitującym transporter zależny od sodu |
WO2005012318A2 (en) | 2003-08-01 | 2005-02-10 | Janssen Pharmaceutica Nv | Substituted fused heterocyclic c-glycosides |
EP1680414A4 (en) | 2003-08-01 | 2009-05-27 | Janssen Pharmaceutica Nv | SUBSTITUTED INDAZOLE-O-GLUCOSIDE |
JP4131216B2 (ja) | 2003-08-20 | 2008-08-13 | Jsr株式会社 | ポリアリーレンおよびその製造方法、ならびに高分子固体電解質およびプロトン伝導膜 |
US7375090B2 (en) * | 2003-08-26 | 2008-05-20 | Boehringer Ingelheim International Gmbh | Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof |
ATE422204T1 (de) | 2003-08-26 | 2009-02-15 | Boehringer Ingelheim Int | Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
US20050085680A1 (en) * | 2003-10-21 | 2005-04-21 | Joseph Auerbach | Method for industrial decontamination |
US7371732B2 (en) * | 2003-12-22 | 2008-05-13 | Boehringer Ingelheim International Gmbh | Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture |
DE10361133A1 (de) | 2003-12-22 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Glucopyranosyloxy-substituierte Aromaten, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
ZA200606792B (en) | 2004-03-04 | 2007-12-27 | Kissei Pharmaceutical | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof |
US8058245B2 (en) | 2004-03-04 | 2011-11-15 | Kissei Pharmaceutical Co., Ltd. | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof |
DE102004012676A1 (de) * | 2004-03-16 | 2005-10-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Glucopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
EP2295422A3 (de) | 2004-03-16 | 2012-01-04 | Boehringer Ingelheim International GmbH | Glucopyranosylsubstituierte Benzolderivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US7393836B2 (en) | 2004-07-06 | 2008-07-01 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
MX2007000209A (es) | 2004-07-08 | 2007-03-30 | Astellas Pharma Inc | Proceso para la produccion de derivados de azuleno e intermediarios para la sintesis de los mismos. |
DE102004034690A1 (de) | 2004-07-17 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
TW200606129A (en) | 2004-07-26 | 2006-02-16 | Chugai Pharmaceutical Co Ltd | Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same |
WO2006010557A1 (de) * | 2004-07-27 | 2006-02-02 | Boehringer Ingelheim International Gmbh | D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
WO2006018150A1 (de) * | 2004-08-11 | 2006-02-23 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
AR051446A1 (es) * | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
EP1803729A4 (en) | 2004-09-29 | 2008-10-01 | Kissei Pharmaceutical | HETEROCYCLIC NITROGENIC COMPOUND 1- (-D-GLYCOPYRANOSYL) -3-SUBSTITUTED, THERAPEUTIC PREPARATION CONTAINING SAID COMPOUND, AND MEDICAL USE OF SAID COMPOUND |
DE102004048388A1 (de) | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
EP1828216B1 (en) * | 2004-12-16 | 2008-09-10 | Boehringer Ingelheim International GmbH | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
JP2006176443A (ja) | 2004-12-22 | 2006-07-06 | Shionogi & Co Ltd | メラニン凝集ホルモン受容体アンタゴニスト |
GB0428180D0 (en) * | 2004-12-23 | 2005-01-26 | Biopartners Ltd | Combination therapy |
GT200600008A (es) | 2005-01-18 | 2006-08-09 | Formulacion de compresion directa y proceso | |
WO2006089872A1 (en) * | 2005-02-23 | 2006-08-31 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted ( (hetero)arylethynyl-benzyd-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors |
ES2338041T3 (es) * | 2005-04-15 | 2010-05-03 | Boehringer Ingelheim International Gmbh | Derivados de (heteroariloxi-bencil)-benceno sustituidos con glucopiranosilo en calidad de inhibidores de sglt. |
US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
UA91546C2 (uk) | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
US7772191B2 (en) * | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
WO2007000445A1 (en) * | 2005-06-29 | 2007-01-04 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
CA2616294A1 (en) * | 2005-07-27 | 2007-02-08 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted ((hetero)cycloalkylethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter (sglt) inhibitors |
KR100780553B1 (ko) | 2005-08-18 | 2007-11-29 | 한올제약주식회사 | 메트포르민 서방정 및 그의 제조방법 |
US7452872B2 (en) | 2005-08-24 | 2008-11-18 | Salix Pharmaceuticals, Inc. | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
DE602006017566D1 (de) * | 2005-08-30 | 2010-11-25 | Boehringer Ingelheim Pharma | Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür |
ATE491700T1 (de) * | 2005-09-08 | 2011-01-15 | Boehringer Ingelheim Int | KRISTALLINE FORMEN VON 1-CHLORO-4-(ß-D- |
AR056195A1 (es) | 2005-09-15 | 2007-09-26 | Boehringer Ingelheim Int | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos |
JOP20180109A1 (ar) | 2005-09-29 | 2019-01-30 | Novartis Ag | تركيبة جديدة |
SG166115A1 (en) | 2005-09-30 | 2010-11-29 | Boehringer Ingelheim Vetmed | Pharmaceutical preparation containing meloxicam |
EP1989191B1 (en) * | 2006-02-15 | 2011-07-20 | Boehringer Ingelheim International GmbH | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
PE20080697A1 (es) * | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
PE20080251A1 (es) * | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
WO2007144175A2 (en) | 2006-06-16 | 2007-12-21 | Lek Pharmaceuticals D.D. | Pharmaceutical composition comprising hydrochlorothiazide and telmisartan |
PE20080991A1 (es) | 2006-06-27 | 2008-09-05 | Novartis Ag | Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas |
TW200817424A (en) | 2006-08-04 | 2008-04-16 | Daiichi Sankyo Co Ltd | Benzylphenyl glucopyranoside derivatives |
JP5384343B2 (ja) | 2006-08-15 | 2014-01-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルコピラノシル−置換シクロプロピルベンゼン誘導体、そのような化合物を含む医薬組成物、sglt阻害剤としてのそれらの使用及びそれらの製造方法 |
MX2009001763A (es) | 2006-08-17 | 2009-02-25 | Wellstat Therapeutics Corp | Tratamiento combinado para trastornos metabolicos. |
US7858587B2 (en) * | 2006-09-21 | 2010-12-28 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted difluorobenzyl-benzene derivates, medicaments containing such compounds, their use and process for their manufacture |
WO2008049923A1 (en) | 2006-10-27 | 2008-05-02 | Boehringer Ingelheim International Gmbh | CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS |
CL2007003187A1 (es) | 2006-11-06 | 2008-03-07 | Boehringer Ingelheim Int | Compuestos derivados de bencil-benzonitrilo sustituido con glucopiranosilo y sus sales; procedimiento de preparacion; compuestos intermediarios; proceso para preparar los compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de |
WO2008055940A2 (en) | 2006-11-09 | 2008-05-15 | Boehringer Ingelheim International Gmbh | Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions |
WO2008062273A2 (en) | 2006-11-20 | 2008-05-29 | Cadila Pharmaceuticals Limited | Solid oral dosage form having antidiabetic drug combination |
JP2010516721A (ja) | 2007-01-26 | 2010-05-20 | サノフィ−アベンティス | フェノチアジン誘導体、その製造方法及び医薬としてその使用 |
EP2124965A1 (en) * | 2007-01-26 | 2009-12-02 | Boehringer Ingelheim International GmbH | Methods for preventing and treating neurodegenerative disorders |
US7879807B2 (en) * | 2007-02-21 | 2011-02-01 | Boehringer Ingelheim International Gmbh | Tetrasubstituted glucopyranosylated benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
ITFI20070042A1 (it) | 2007-02-21 | 2008-08-22 | Laboratori Guidotti Spa | Formulazione farmaceutica e compressa comprendente detta formulazione. |
WO2008101938A1 (en) | 2007-02-21 | 2008-08-28 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture |
TW200904454A (en) | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof |
PE20090185A1 (es) | 2007-03-22 | 2009-02-28 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
PE20090696A1 (es) | 2007-04-20 | 2009-06-20 | Bristol Myers Squibb Co | Formas cristalinas de saxagliptina y procesos para preparar las mismas |
US20080287529A1 (en) * | 2007-05-18 | 2008-11-20 | Bristol-Myers Squibb Company | Crystal structures of sglt2 inhibitors and processes for preparing same |
PE20090603A1 (es) | 2007-08-16 | 2009-06-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv |
CL2008002427A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
ME03072B (me) * | 2007-09-10 | 2019-01-20 | Janssen Pharmaceutica Nv | Postupak za dobijanje jedinjenja која su korisna као inhibiтori sgl т |
CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
US20100330177A1 (en) | 2008-02-05 | 2010-12-30 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor |
US8551524B2 (en) | 2008-03-14 | 2013-10-08 | Iycus, Llc | Anti-diabetic combinations |
EP2261213A1 (en) | 2008-04-01 | 2010-12-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
AR071175A1 (es) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante |
WO2010045656A2 (en) | 2008-10-17 | 2010-04-22 | Nectid, Inc. | Novel sglt2 inhibitor dosage forms |
NZ619520A (en) | 2009-02-13 | 2015-06-26 | Boehringer Ingelheim Int | Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
CN104906582A (zh) | 2009-02-13 | 2015-09-16 | 勃林格殷格翰国际有限公司 | 包含sglt2抑制剂、dpp-iv抑制剂和任选的另一种抗糖尿病药的药物组合物及其用途 |
AP2011005780A0 (en) * | 2009-02-13 | 2011-08-31 | Boehringer Ingelheim Int | Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient. |
UY32427A (es) * | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
KR20110118668A (ko) * | 2009-02-13 | 2011-10-31 | 베링거 인겔하임 인터내셔날 게엠베하 | 1형 당뇨병, 2형 당뇨병, 내당능 장애 또는 고혈당증을 치료하기 위한 sglt2 억제제 |
PT2419097E (pt) | 2009-04-16 | 2013-10-03 | Taisho Pharmaceutical Co Ltd | Composição farmacêutica compreendendo (1s)-1,5-anidro-1-[5-(4- etoxibenzil)-2-metoxi-4-metilfenil]-1-tio-d-glucitol e metformina e suas utilizações no tratamento da diabetes |
CN106075451A (zh) | 2009-05-27 | 2016-11-09 | 阿斯利康(瑞典)有限公司 | 使用sglt2抑制剂及其组合物在对先前用其它抗糖尿病药进行的治疗具有耐受的患者中治疗ii型糖尿病的方法 |
US20110077212A1 (en) | 2009-09-25 | 2011-03-31 | Theracos, Inc. | Therapeutic uses of sglt2 inhibitors |
CN102574829B (zh) | 2009-09-30 | 2015-07-01 | 贝林格尔.英格海姆国际有限公司 | 吡喃葡萄糖基取代的苄基-苯衍生物的制备方法 |
PL2483286T3 (pl) | 2009-09-30 | 2017-04-28 | Boehringer Ingelheim International Gmbh | Sposób wytwarzania postaci krystalicznej 1-chloro-4-(β-D-glukopiranoz-1-ylo)-2-[4-((S)-tetrahydrofuran-3-yloksy)-benzylo]-benzenu |
UY32919A (es) | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos |
CA2780941C (en) | 2009-11-13 | 2018-06-12 | Bristol-Myers Squibb Company | Immediate release tablet formulations |
WO2011120923A1 (en) | 2010-03-30 | 2011-10-06 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof |
JP5837072B2 (ja) | 2010-09-03 | 2015-12-24 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 水溶性抗酸化剤を使用する製剤 |
US20120283169A1 (en) | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
RU2607480C2 (ru) | 2011-02-01 | 2017-01-10 | Бристол-Майерс Сквибб Компани | Фармацевтические композиции, содержащие аминосоединение |
US20130035281A1 (en) | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
JP5835598B2 (ja) | 2011-06-03 | 2015-12-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 神経弛緩剤で治療されている患者において代謝性障害を治療するためのsglt−2阻害剤 |
US20130035298A1 (en) | 2011-07-08 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
DE102011109492A1 (de) | 2011-08-04 | 2013-02-07 | GM Global Technology Operations LLC (n. d. Gesetzen des Staates Delaware) | Fahrunterstützungsvorrichtung zur Unterstützung der Befahrung enger Fahrwege |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
PT2981271T (pt) | 2013-04-05 | 2019-02-19 | Boehringer Ingelheim Int | Utilizações terapêuticas de empagliflozina |
US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US20160000816A1 (en) | 2013-04-05 | 2016-01-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
MX2021004308A (es) | 2013-04-18 | 2022-10-26 | Boehringer Ingelheim Int | Empagliflozina para usarse en el tratamiento de micro y macroalbuminuria. |
DK3721882T3 (da) | 2014-04-01 | 2024-10-21 | Boehringer Ingelheim Vetmedica Gmbh | Behandling af hypofyse pars intermedia-dysfunktion hos hestedyr |
US20170106009A1 (en) | 2015-10-15 | 2017-04-20 | Boehringer Ingelheim International Gmbh | Methods of treating diseases |
-
2010
- 2010-09-24 CN CN201080042705.XA patent/CN102574829B/zh active Active
- 2010-09-24 ES ES10762899.2T patent/ES2546762T3/es active Active
- 2010-09-24 KR KR1020127008072A patent/KR101813025B1/ko active Active
- 2010-09-24 EP EP10762899.2A patent/EP2486029B1/en active Active
- 2010-09-24 EA EA201200537A patent/EA022032B1/ru not_active IP Right Cessation
- 2010-09-24 BR BR112012007085A patent/BR112012007085B8/pt active IP Right Grant
- 2010-09-24 PL PL10762899T patent/PL2486029T3/pl unknown
- 2010-09-24 PH PH1/2012/500634A patent/PH12012500634A1/en unknown
- 2010-09-24 CA CA2775962A patent/CA2775962C/en active Active
- 2010-09-24 IN IN2751DEN2012 patent/IN2012DN02751A/en unknown
- 2010-09-24 NZ NZ598366A patent/NZ598366A/en unknown
- 2010-09-24 DK DK10762899.2T patent/DK2486029T3/en active
- 2010-09-24 AU AU2010303124A patent/AU2010303124B2/en active Active
- 2010-09-24 HU HUE10762899A patent/HUE026133T2/en unknown
- 2010-09-24 SI SI201031009T patent/SI2486029T1/sl unknown
- 2010-09-24 WO PCT/EP2010/064120 patent/WO2011039108A2/en active Application Filing
- 2010-09-24 PT PT107628992T patent/PT2486029E/pt unknown
- 2010-09-24 JP JP2012531333A patent/JP5758900B2/ja active Active
- 2010-09-24 HR HRP20150945TT patent/HRP20150945T1/hr unknown
- 2010-09-28 US US12/892,326 patent/US9024010B2/en active Active
- 2010-09-29 TW TW099133084A patent/TWI465458B/zh active
- 2010-09-29 AR ARP100103544A patent/AR078193A1/es active IP Right Grant
- 2010-10-20 MX MX2012003048A patent/MX2012003048A/es active IP Right Grant
-
2012
- 2012-02-14 IL IL218101A patent/IL218101A0/en active IP Right Grant
- 2012-03-02 CL CL2012000581A patent/CL2012000581A1/es unknown
-
2015
- 2015-04-07 US US14/680,318 patent/US9873714B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5758900B2 (ja) | グルコピラノシル置換ベンジルベンゼン誘導体の調製方法 | |
WO2015101916A1 (en) | Process for the preparation of empagliflozin | |
WO2019208571A1 (ja) | アミダイト化合物及び該化合物を用いたポリヌクレオチドの製造方法 | |
EP3483161B1 (en) | Intermediates used to make entecavir | |
JP2021193102A (ja) | 1−シアノ−2−(4−シクロプロピル−ベンジル)−4−(β−D−グルコピラノス−1−イル)−ベンゼン、L−プロリンおよび水からなる1:1:1共結晶の合成 | |
HU207288B (en) | Process for enenthioselective producing phenyl-isoserine derivatives | |
WO2007049295A2 (en) | An improved one pot process for making key intermediate for gemcitabine hcl | |
JP2007538041A (ja) | ジフェニルアゼチジノン誘導体の製造方法 | |
CN101277966A (zh) | 合成HMG-CoA还原酶抑制剂的方法 | |
KR100634249B1 (ko) | 파클리탁셀 c-4 메틸 카르보네이트 동족체의 제조 방법 | |
JPS5936914B2 (ja) | セフアロスポリン類縁体 | |
KR101259648B1 (ko) | 2′,2′-디플루오로뉴클레오시드 및 중간체의 새로운 제조방법 | |
RU2394835C2 (ru) | Способ получения тиофенгликозидных производных | |
AU677986B2 (en) | N-substituted 2-azetidinones | |
KR101032761B1 (ko) | 도세탁셀의 제조방법 및 도세탁셀의 제조를 위한 신규한중간체 | |
EP2164839A2 (en) | Process for the preparation of orlistat | |
JPWO2003080561A1 (ja) | ボグリボースの製造法 | |
KR20160098495A (ko) | 엠파글리플로진의 제조방법 | |
JPH0267250A (ja) | 2,2‐ジフルオロ‐3‐ヒドロキシカルボン酸誘導体の製造法 | |
JP2021095367A (ja) | C−アリールグリコシド誘導体の製造方法 | |
WO2002051852A1 (fr) | Procede de production d'un derive de saccharide non naturel | |
JP2002356492A (ja) | 非天然型糖誘導体の製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131125 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140219 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140226 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140526 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141008 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150108 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150518 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150604 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5758900 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |